“We have been taking new policy steps at the FDA to support downward pressure on drug prices by helping to clear a path for more efficient generic development,” says FDA Commissioner Scott Gottlieb, M.D.
Patients are becoming increasingly knowledgeable about their personal health and about the healthcare options available to them – and that is a good thing.
This webinar, moderated by Ogilvy Consulting’s Ritesh Patel and led by Ogilvy Health’s Angelo Campano and Chris Andrews, will focus on the use of data in healthcare marketing. The webinar will take a closer look at Ogilvy Consulting’s Tripl offering, a proprietary platform that connects data, people and technology, illustrated with real market examples.
For years and years, pharmaceutical pricing has been under attack by consumers, professionals, and payers. More recently, the U.S. government has dramatically stepped up its assault, with price reduction proposals from Congress and stern words from President Trump indicating that drug pricing is a major ongoing focus of the administration. The 2018 timeline was dotted with government jabs at pharma pricing, as well as some attempts to take real action.
A sales rep preparing for her week isn’t thinking, What’s in my sales dashboard? What is my progress towards my call plan? She’s thinking, What are the burning issues in my territory this week? How should I adjust my plan based on the latest events and information that I have? Then she manually navigates her way through dashboards and reports to find these answers.
The market research company Gartner predicts that consumer demand for voice devices such as Amazon Echo and Google Home will generate $3.5 billion by 2021. These intelligent voice assistants, plus other digital technologies such as the Apple Watch, are slowly but steadily being adopted in healthcare.
Ogilvy Health recently asked some of its agency leaders – in creative, payer, digital, planning, and account – to share what they’re tracking in 2019.
In the era of precision medicine, life sciences companies are transforming customer engagement with complete, accurate and up-to-date customer data.
Most pharmaceutical brands are really happy with a handful of their agencies, satisfied with some, and not too thrilled with one or two. TGaS uncovered four areas to watch in 2019 through its benchmark-based consultancy.
With reports that the House Democratic leadership has agreed to hearings on Medicare for All, and a Harvard/Politico survey demonstrating that 84 percent of Democrats support a tax-funded national healthcare plan, the concept of Medicare for All is moving into the healthcare debate. At this point, however, Medicare for All is a concept defined by only general terms.
Sorry. No data so far.
Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.
February 2019 Focus: Agenda 2019, Top 10 Pipelines To Watch, Value Of Pharmaceuticals, and more!
